Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach
Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach
复制标题
DOI：
10.1155/2020/2683286
复制
发表时间：
2020-05-11
影响因子：
--
通讯作者：
Makhawi, Abdelrafie M.
中科院分区：
文献类型：
--
作者：
Abdelmageed, Miyssa I.;Abdelmoneim, Abdelrahman H.;Makhawi, Abdelrafie M.
背景2019年12月，一种新的地方病在中国武汉市蔓延。几周内，世界卫生组织（WHO）宣布了一种新型冠状病毒，命名为2019冠状病毒病（COVID-19）。2020年1月下旬，世卫组织宣布疫情为“国际关注的突发公共卫生事件”，原因是疫情在全球范围内迅速蔓延并呈上升趋势。目前，对于这种新出现的感染没有疫苗或批准的治疗方法;因此，本研究的目的是使用免疫信息学方法设计针对COVID-19的多表位肽疫苗。法使用了促进免疫信息学方法和比较基因组学方法组合的几种技术，以确定使用2019-nCoV的包膜蛋白作为靶标设计基于T细胞表位的肽疫苗的潜在肽。结果在COVID-19菌株中通过比较测序发现了广泛的突变、插入和缺失。此外，发现与MHC I类和MHC II类结合的10种肽是用于疫苗设计的有希望的候选物，分别具有足够的88.5%和99.99%的世界人口覆盖率。结论基于T细胞表位的肽疫苗是针对COVID-19设计的，使用包膜蛋白作为免疫原性靶标。然而，拟议的疫苗需要迅速进行临床验证，以确保其安全性和免疫原性，以帮助在导致毁灭性的全球疫情之前阻止这一流行病。
Background. A new endemic disease has spread across Wuhan City, China, in December 2019. Within few weeks, the World Health Organization (WHO) announced a novel coronavirus designated as coronavirus disease 2019 (COVID-19). In late January 2020, WHO declared the outbreak of a "public-health emergency of international concern" due to the rapid and increasing spread of the disease worldwide. Currently, there is no vaccine or approved treatment for this emerging infection; thus, the objective of this study is to design a multiepitope peptide vaccine against COVID-19 using an immunoinformatics approach. Method. Several techniques facilitating the combination of the immunoinformatics approach and comparative genomic approach were used in order to determine the potential peptides for designing the T-cell epitope-based peptide vaccine using the envelope protein of 2019-nCoV as a target. Results. Extensive mutations, insertion, and deletion were discovered with comparative sequencing in the COVID-19 strain. Additionally, ten peptides binding to MHC class I and MHC class II were found to be promising candidates for vaccine design with adequate world population coverage of 88.5% and 99.99%, respectively. Conclusion. The T-cell epitope-based peptide vaccine was designed for COVID-19 using the envelope protein as an immunogenic target. Nevertheless, the proposed vaccine rapidly needs to be validated clinically in order to ensure its safety and immunogenic profile to help stop this epidemic before it leads to devastating global outbreaks.